Nadine Tung
YOU?
Author Swipe
View article: Supplemental Figure 3 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 3 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer Open
Supplemental Figure 3: Plasma circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics determined with ULP-WGS
View article: Supplemental Figure 5 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer
Supplemental Figure 5 from Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer Open
Supplemental Figure 5: SSNVs detected in the cancer-related genes across 68 ctDNA WES samples
View article: Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030) Open
Background Tumor-infiltrating lymphocytes (TILs), assessed by visual examination, are prognostic and predictive in early-stage triple-negative breast cancer. Computational assessment may provide a complementary approach. We evaluated the p…
View article: Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER⁺ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer
Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER⁺ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer Open
Background We investigated the impact of gender-affirming testosterone therapy (TT) on breast cancer (BC) risk and tumor progression. Materials and methods We leveraged a large human breast tissue dataset (n=417) to assess TT and terminal …
View article: P264: Survival from ER-positive breast cancer in women who carry a BRCA1 mutation
P264: Survival from ER-positive breast cancer in women who carry a BRCA1 mutation Open
View article: HER2DX genomic test in early-stage HER2-positive breast cancer
HER2DX genomic test in early-stage HER2-positive breast cancer Open
Therapies targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer significantly impact patient outcomes, quality of life, and health care systems. While chemotherapy and trastuzumab improve survival in early-stage …
View article: HER2DX genomic test in early-stage HER2-positive breast cancer
HER2DX genomic test in early-stage HER2-positive breast cancer Open
Therapies targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer significantly impact patient outcomes, quality of life, and health care systems. While chemotherapy and trastuzumab improve survival in early-stage …
View article: Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i>
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in <i>BRCA1</i> and <i>BRCA2</i> Open
PURPOSE It is uncertain whether, and to what extent, hormonal contraceptives increase breast cancer (BC) risk for germline BRCA1 or BRCA2 mutation carriers. METHODS Using pooled observational data from four prospective cohort studies, asso…
View article: BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing Open
View article: Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial) Open
PURPOSE The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce this time commitment. This stud…
View article: Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT Open
PURPOSE Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)–positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need…
View article: MRI Surveillance and Breast Cancer Mortality in Women With <i>BRCA1</i> and <i>BRCA2</i> Sequence Variations
MRI Surveillance and Breast Cancer Mortality in Women With <i>BRCA1</i> and <i>BRCA2</i> Sequence Variations Open
Importance Magnetic resonance imaging (MRI) surveillance is offered to women with a pathogenic variant in the BRCA1 or BRCA2 gene who face a high lifetime risk of breast cancer. Surveillance with MRI is effective in downstaging breast canc…
View article: Bilateral Oophorectomy and All-Cause Mortality in Women With <i>BRCA1</i> and <i>BRCA2</i> Sequence Variations
Bilateral Oophorectomy and All-Cause Mortality in Women With <i>BRCA1</i> and <i>BRCA2</i> Sequence Variations Open
Importance Preventive bilateral salpingo-oophorectomy is offered to women at high risk of ovarian cancer who carry a pathogenic variant in BRCA1 or BRCA2 ; however, the association of oophorectomy with all-cause mortality has not been clea…
View article: Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis Open
View article: TABLE 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
TABLE 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Association between moderate physical activity (in MET-hours/week) and ovarian cancer among women with a BRCA1 or BRCA2 mutation
View article: Supplementary Table 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Supplementary Table 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Supplementary Table 3 shows the association between moderate physical activity (in MET-hr/week) and ovarian cancer among women with a BRCA1 or BRCA2 mutation, stratified by BMI at age 18.
View article: Supplementary Table 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Supplementary Table 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Supplementary Table 2 shows the association between total physical activity (in MET-hr/week) and ovarian cancer among women with a BRCA1 or BRCA2 mutation, stratified by BRCA mutation type and menopausal status.
View article: Supplementary Table 5 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Supplementary Table 5 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Supplementary Table 5 shows the association between total physical activity (in MET-hr/week) and ovarian cancer among women with a BRCA1 or BRCA2 mutation, stratified by BMI at age 18.
View article: TABLE 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
TABLE 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Association between vigorous physical activity (in MET-hours/week) and ovarian cancer among women with a BRCA1 or BRCA2 mutation
View article: Supplementary Table 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Supplementary Table 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Supplementary Table S4 shows the association between vigorous physical activity (in MET-hr/week) and ovarian cancer among women with a BRCA1 or BRCA2 mutation, stratified by BMI at age 18.
View article: Supplementary Table 6 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Supplementary Table 6 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Supplementary Table 6 shows the association between physical activity overall (in MET-hr/week) and ovarian cancer among women with a BRCA1 or BRCA2 mutation.
View article: FIGURE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
FIGURE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Flow diagram describing subject selection.
View article: Supplementary Table 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Supplementary Table 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Supplementary Table 2 shows the association between total physical activity (in MET-hr/week) and ovarian cancer among women with a BRCA1 or BRCA2 mutation, stratified by BRCA mutation type and menopausal status.
View article: Supplementary Table 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Supplementary Table 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Supplementary Table S4 shows the association between vigorous physical activity (in MET-hr/week) and ovarian cancer among women with a BRCA1 or BRCA2 mutation, stratified by BMI at age 18.
View article: Supplementary Table 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Supplementary Table 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Supplementary Table 1 shows a summary of the steps to create exposure variables.
View article: TABLE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
TABLE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Comparison of cases and controls with a BRCA1 or BRCA2 mutation
View article: Data from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Data from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
In the general population, physical activity has been associated with a lower risk of several cancers; however, the evidence for ovarian cancer is not clear. It is suggested that early-life physical activity may differentially impact risk.…
View article: TABLE 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
TABLE 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Association between total physical activity (in MET-hours/week) and ovarian cancer among women with a BRCA1 or BRCA2 mutation
View article: Data from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Data from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
In the general population, physical activity has been associated with a lower risk of several cancers; however, the evidence for ovarian cancer is not clear. It is suggested that early-life physical activity may differentially impact risk.…
View article: Supplementary Table 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation
Supplementary Table 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation Open
Supplementary Table 1 shows a summary of the steps to create exposure variables.